Published in Fed Proc on July 06, 1971
Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action. J Clin Invest (1975) 0.97
Microbodies in experimentally altered cells. IX. The fate of microbodies. Am J Pathol (1972) 0.84
The effect of clofibrate on cholesterol induced aortic lesions. Br J Exp Pathol (1972) 0.77
Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (1980) 2.85
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol (1966) 2.29
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Chronic alcoholism with fatty metamorphosis of the liver. Mitochondrial alterations in hepatic cells. Am J Pathol (1964) 1.76
Pharmacokinetics of methotrexate. Clin Pharmacol Ther (1973) 1.55
The effect of spironolactone on antipyrine metabolism in man. Pharmacology (1973) 1.31
Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology (1993) 1.30
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol (1974) 1.28
Absorption of orally given digoxin preparations. JAMA (1972) 1.27
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet (1977) 1.25
Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22
Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response. J Cell Biol (1974) 1.21
Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rat and mice. Life Sci (1976) 1.14
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Acute exposure to cadmium causes severe liver injury in rats. Toxicol Appl Pharmacol (1982) 1.10
Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver. Cancer Res (1979) 1.09
Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms. J Pharm Sci (1978) 1.09
Susceptibility of an ibred strain of guinea pigs to the induction of pancreatic adenocarcinoma by N-methyl-N-nitrosourea. J Natl Cancer Inst (1974) 1.08
Drugs and drug metabolites as environmental contaminants: chlorophenoxyisobutyrate and salicyclic acid in sewage water effluent. Life Sci (1977) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
Malignant tumors in rats given lasiocarpine. Cancer Res (1972) 1.06
Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med (1972) 1.04
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res (1979) 1.00
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (1972) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet (1978) 0.99
Pathology of the liver in Reye's syndrome. Lab Invest (1975) 0.97
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther (1977) 0.95
A comparative study of drug metabolism in the isolated perfused liver and in vivo in rats. Eur J Pharmacol (1970) 0.95
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Drug interactions. Pharmacol Physicians (1970) 0.93
Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther (1969) 0.93
Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res (1974) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Long term effects of aflatoxin B1 and viral hepatitis on marmoset liver. A preliminary report. Lab Invest (1974) 0.91
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Multiple congenital mesenchymal tumors. Multiple vascular leiomyomas in several organs of a newborn. Cancer (1971) 0.87
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet (1983) 0.87
Absorption and excretion of clindamycin-2-phosphate in children after intramuscular injection. Clin Pharmacol Ther (1972) 0.86
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
Alterations in rat testes due to an antispermatogenic agent. Light and electron microscopic study. Arch Pathol (1967) 0.86
Time course of cadmium-induced ultrastructural changes in rat liver. Toxicol Appl Pharmacol (1984) 0.86
Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643. Arch Int Pharmacodyn Ther (1978) 0.85
Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin Pharmacol Ther (1974) 0.85
Association between clinical cardiac status, laboratory parameters, and digoxin usage. Am Heart J (1976) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Dispos (1981) 0.84
Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis (1977) 0.84
Ultrastructure of nasopharyngeal angiofibromas. Cancer (1966) 0.84
Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci (1974) 0.83
Diphenylhydantoin potency and plasma protein binding. J Pharmacol Exp Ther (1975) 0.83
Unusual responses of rat hepatic and renal peroxisomes to RMI 14, 514, a new hypolipidemic agent. J Cell Biol (1978) 0.83
Pancreatic necrosis and regeneration induced by 4-hydroxyaminoquinoline-1-oxide in the guinea pig. Lab Invest (1975) 0.83
1-methyl-4piperidyl-bis (P-chlorophenoxy) acetate: a new hypolipidemic peroxisome proliferator. Res Commun Chem Pathol Pharmacol (1975) 0.82
Induction of liver tumors by aflatoxin B1 in the tree shrew (Tupaia glis), a nonhuman primate. Cancer Res (1976) 0.82
Metabolic disposition of antipyrine in patients with lung cancer. Cancer Res (1977) 0.82
Topical application of lindane cream (Kwell) and antipyrine metabolism. J Invest Dermatol (1980) 0.81
Pharmacology of hypolipidemic drugs. Introduction. Fed Proc (1971) 0.81
Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther (1978) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Metabolic responses to plasma concentrations of theophylline. Clin Pharmacol Ther (1979) 0.81
Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentography. J Chromatogr (1978) 0.81
Primary carcinoma of the liver as a pathologist's problem. Pathol Annu (1970) 0.80
Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin Pharmacokinet (1990) 0.80
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Protein deficiency in rhesus monkeys. Am J Pathol (1966) 0.80
Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions. Clin Toxicol (1971) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Response of microperoxisomes in rat small intestinal mucosa to CPIB, a hypolipidemic drug. Biochem Pharmacol (1976) 0.80
Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther (1978) 0.79
Species differences in the plasma protein binding of desipramine. J Pharm Pharmacol (1968) 0.79
Lysosomal activity in sertoli cells of normal and degenerating seminiferous epithelium of rat testes: an ultrastructural and biochemical study. Am J Pathol (1967) 0.79
Serum digitoxin in uremic patients. Clin Pharmacol Ther (1972) 0.79
The effect of DDD on barbiturate and steroid-induced hypnosis in the dog and rat. Biochem Pharmacol (1966) 0.79
Angiotensin-I-converting enzyme in cancer patients. J Clin Oncol (1984) 0.79
Placental transfer and fetal urinary excretion of gentamicin during constant rate maternal infusion. Pediatr Res (1975) 0.78
The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin. Ann N Y Acad Sci (1973) 0.78
Bioavailability of aminosalicylic acid and its various salts in humans IV: comparison of four brands of the sodium salt. J Pharm Sci (1974) 0.78
Hepatic catalase is not essential for the hypolipidemic action of peroxisome proliferators. Proc Soc Exp Biol Med (1977) 0.78
Identification of the hepatic microbody membrane in freeze-fracture replicas. Lab Invest (1974) 0.78
Laslocarpine-induced, transplantable squamous cell carcinoma of rat skin. J Natl Cancer Inst (1974) 0.78
Effect of hydrazine sulfate on glucose-regulating enzymes in the normal and cancerous rat. Immunopharmacology (1989) 0.77
Natural segregation of nucleolar components of liver cells in newts. J Ultrastruct Res (1972) 0.77
Inhibition of amphetamine tolerance and metabolism by propranolol. J Pharmacol Exp Ther (1974) 0.77
Studies of the larynx after teflon injection. Arch Otolaryngol (1966) 0.77
Bioavailability studies on p-aminosalicylic acid and its various salts in man. II. Comparison of parasal and pascorbic. Am Rev Respir Dis (1973) 0.76
Beckwith-Wiedemann syndrome. Wilms' tumor, cardiac hamartoma, persistent visceromegaly, and glomeruloneogenesis in a 2-year-old boy. Arch Pathol (1972) 0.76